ECSP10010622A - Composición farmacéutica que comprende una sal de estroncio, vitamina d y una ciclodextrina - Google Patents

Composición farmacéutica que comprende una sal de estroncio, vitamina d y una ciclodextrina

Info

Publication number
ECSP10010622A
ECSP10010622A EC2010010622A ECSP10010622A ECSP10010622A EC SP10010622 A ECSP10010622 A EC SP10010622A EC 2010010622 A EC2010010622 A EC 2010010622A EC SP10010622 A ECSP10010622 A EC SP10010622A EC SP10010622 A ECSP10010622 A EC SP10010622A
Authority
EC
Ecuador
Prior art keywords
vitamin
pharmaceutical composition
cyclodextrine
strontium salt
strontium
Prior art date
Application number
EC2010010622A
Other languages
English (en)
Inventor
Jean-Manuel Pean
Gilles Briault
Xavier Quenault
Cecile Poirier
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41719206&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010622(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of ECSP10010622A publication Critical patent/ECSP10010622A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composición farmacéutica que comprende una sal de estroncio, vitamina D y una ciclodextrina.
EC2010010622A 2009-11-27 2010-11-22 Composición farmacéutica que comprende una sal de estroncio, vitamina d y una ciclodextrina ECSP10010622A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0905706A FR2953139B1 (fr) 2009-11-27 2009-11-27 Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine

Publications (1)

Publication Number Publication Date
ECSP10010622A true ECSP10010622A (es) 2011-06-30

Family

ID=41719206

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010622A ECSP10010622A (es) 2009-11-27 2010-11-22 Composición farmacéutica que comprende una sal de estroncio, vitamina d y una ciclodextrina

Country Status (31)

Country Link
US (1) US20110130370A1 (es)
EP (1) EP2335704A1 (es)
JP (1) JP2011111458A (es)
KR (1) KR101278935B1 (es)
CN (1) CN102078620A (es)
AP (1) AP2010005490A0 (es)
AR (1) AR079160A1 (es)
AU (1) AU2010241527B2 (es)
BR (1) BRPI1004685A2 (es)
CA (1) CA2723119C (es)
CL (1) CL2010001260A1 (es)
CO (1) CO6280058A1 (es)
CU (1) CU20100230A7 (es)
EA (1) EA018460B1 (es)
EC (1) ECSP10010622A (es)
FR (1) FR2953139B1 (es)
GE (1) GEP20135734B (es)
HN (1) HN2010002518A (es)
IL (1) IL209348A0 (es)
MA (1) MA32363B1 (es)
MX (1) MX2010012566A (es)
MY (1) MY158261A (es)
NZ (1) NZ589513A (es)
PE (1) PE20110407A1 (es)
SG (1) SG171542A1 (es)
SV (1) SV2010003744A (es)
TW (1) TW201200136A (es)
UA (1) UA105766C2 (es)
UY (1) UY33039A (es)
WO (1) WO2011064474A1 (es)
ZA (1) ZA201008230B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2882048C (en) 2006-02-03 2020-03-24 Opko Renal, Llc Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
HUE037309T2 (hu) 2006-06-21 2018-08-28 Opko Ireland Global Holdings Ltd Terápia D-vitamin telítési szer alkalmazásával és D-vitamin hormon helyettesítõ szer
ES2401205T3 (es) 2007-04-25 2013-04-17 Cytochroma Inc. Composiciones de orales de liberación controlada que comprende un compuesto de vitamina D y un soporte céreo
WO2009047644A2 (en) 2007-04-25 2009-04-16 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
SG10201407881WA (en) 2009-11-27 2015-01-29 Genzyme Corp An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
CN103037902A (zh) 2010-03-29 2013-04-10 赛特克罗公司 用于降低甲状旁腺水平的方法和组合物
CN102525975B (zh) * 2011-12-14 2013-06-19 天津药物研究院药业有限责任公司 雷奈酸锶口腔崩解片及其制备方法
CN102626420B (zh) * 2012-04-13 2014-06-25 深圳大学 一种含有锶、钙和维生素d的混合制剂
ES2505716T3 (es) * 2013-01-21 2015-09-04 Galenicum Health S.L. Composiciones farmacéuticas que comprenden una sal de ácido
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
CN103142623B (zh) * 2013-03-21 2014-04-16 青岛正大海尔制药有限公司 骨化三醇和雷尼酸锶的混悬颗粒及其制备方法
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
EP3235822B1 (en) * 2014-12-19 2020-01-29 Nagasaki University Novel bisphosphonic acid derivative and application for same
EP4596045A3 (en) 2016-03-28 2025-10-15 EirGen Pharma Ltd. Methods of vitamin d treatment
US10463636B2 (en) * 2016-09-30 2019-11-05 Deanna J. Nelson Pharmaceutical quality strontium L-lactate
WO2018200736A2 (en) * 2017-04-25 2018-11-01 The Buck Institute For Research On Aging Formulations for extending lifespan and healthspan
WO2019004984A2 (en) * 2017-05-29 2019-01-03 Biofarma Ilac Sanayi Ve Ticaret A.S. PHARMACEUTICAL FORMULATION COMPRISING CHOLECALCIFEROL
CN109276710A (zh) * 2018-11-23 2019-01-29 中国医学科学院药用植物研究所海南分所 一种增加骨密度的组合物及其制备方法和用途
CN112370429A (zh) * 2019-10-21 2021-02-19 广州富诺营养科技有限公司 一种直压型有机钙维生素d3咀嚼片及其制备方法
CN114452259A (zh) * 2021-07-28 2022-05-10 安徽旺盛添加剂有限公司 一种维生素d微囊钙片及其制备方法
WO2024246793A1 (en) * 2023-05-31 2024-12-05 Haleon Us Holdings Llc Active ingredient complex and method of making thereof
CN119055788A (zh) * 2023-05-31 2024-12-03 葛兰素史克消费保健（美国）控股有限责任公司 活性成分络合物及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52130904A (en) * 1976-04-26 1977-11-02 Teijin Ltd Stabilization of vitamin d#
HU177586B (en) * 1978-12-19 1981-11-28 Chinoin Gyogyszer Es Vegyeszet New process for preparing stable inclusion complexes of vitamine d with cyclodextrin
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
FR2651497B1 (fr) 1989-09-01 1991-10-25 Adir Nouveaux sels de metaux bivalents de l'acide n, n-di (carboxymethyl)amino-2 cyano-3 carboxymethyl-4 carboxy-5 thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant.
CN1110275A (zh) * 1994-04-06 1995-10-18 福建省药品检验所 一种维生素D与羟丙基-β-环糊精的包合物
FR2749759B1 (fr) 1996-06-17 1999-11-26 Adir Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose
CA2391008C (en) * 1999-11-12 2009-12-22 Pitha & Pitha Llc Crystalline mixtures of partial methyl ethers of beta-cyclodextrin and related compounds
JP2003518515A (ja) * 1999-12-23 2003-06-10 セレスター ホールディング ベー ヴェー 安定化シクロデキストリン複合体
JP2003268005A (ja) * 2002-03-14 2003-09-25 Medorekkusu:Kk 包接体の製造法
ES2275218T3 (es) 2003-05-07 2007-06-01 Osteologix A/S Sales de estroncio hidrosolubles para el tratamiento de afecciones de cartilagos y/o huesos.
SI1622630T1 (sl) 2003-05-07 2012-12-31 Osteologix A/S Stroncijeva kombinacije za profilakso/zdravljenje patologij hrustanca in/ali kosti
JP5049589B2 (ja) * 2003-05-07 2012-10-17 オステオロジックス エイ／エス ストロンチウム塩含有の放出制御組成物
CN100374632C (zh) * 2003-05-30 2008-03-12 三井化学株式会社 人造毛发用纤维
CA2531136A1 (en) * 2003-07-04 2005-01-13 Nycomed Danmark Aps Parathyroid hormone (pth) containing pharmaceutical compositions for oral use
WO2005123130A2 (en) * 2004-06-17 2005-12-29 Osteologix A/S Improved treatments of rheumatic and arthritic diseases comprising combinations of a 5-lipoxygenase inhibitor
EA011814B1 (ru) * 2004-06-25 2009-06-30 Стронтин Апс Композиции, содержащие стронций и витамин d, и их применение
CN101018586B (zh) * 2004-06-25 2014-08-27 莫克瓦洛Spf有限公司 含锶和维生素d的组合物及其用途
EP1865929A2 (en) * 2005-03-28 2007-12-19 Bioresponse, L.L.C. Diindolylmethane-based compositions and methods of use thereof for promoting oral mucosal and bone health
DE102005017775A1 (de) * 2005-04-13 2006-10-19 Schering Ag Komplexe aus Vitamin D-Verbindungen oder deren Analoga mit einem 5Z,7E,10(19)-Trien-System und methlierten Derivaten des ß-Cyclodextrins
US20070218111A1 (en) * 2006-03-16 2007-09-20 Western Holdings, Llc Strontium compositions for bones
CN1823764A (zh) * 2006-03-27 2006-08-30 重庆医药工业研究院有限责任公司 一种含有雷奈酸锶和维生素d药物组合物
FR2899895B1 (fr) 2006-04-12 2010-09-17 Servier Lab Nouveaux sels de strontium d'acides sulfoniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR100822133B1 (ko) * 2006-11-06 2008-04-15 한미약품 주식회사 비타민 ｄ 또는 이의 유도체의 고체분산체 및비스포스포네이트를 포함하는, 골다공증 예방 또는 치료용복합제제

Also Published As

Publication number Publication date
AP2010005490A0 (en) 2010-12-31
WO2011064474A1 (fr) 2011-06-03
FR2953139B1 (fr) 2012-04-13
CL2010001260A1 (es) 2012-02-17
EA201001710A2 (ru) 2011-06-30
AR079160A1 (es) 2011-12-28
JP2011111458A (ja) 2011-06-09
MX2010012566A (es) 2011-05-26
TW201200136A (en) 2012-01-01
UY33039A (es) 2011-04-29
NZ589513A (en) 2012-06-29
AU2010241527B2 (en) 2013-12-19
KR20110059546A (ko) 2011-06-02
CO6280058A1 (es) 2011-05-20
HN2010002518A (es) 2012-09-03
EA018460B1 (ru) 2013-08-30
IL209348A0 (en) 2011-02-28
CA2723119C (fr) 2013-08-06
UA105766C2 (uk) 2014-06-25
CA2723119A1 (fr) 2011-05-27
PE20110407A1 (es) 2011-07-02
MY158261A (en) 2016-09-30
SG171542A1 (en) 2011-06-29
EP2335704A1 (fr) 2011-06-22
EA201001710A3 (ru) 2011-08-30
MA32363B1 (fr) 2011-06-01
KR101278935B1 (ko) 2013-06-28
FR2953139A1 (fr) 2011-06-03
GEP20135734B (en) 2013-01-25
BRPI1004685A2 (pt) 2013-03-05
AU2010241527A1 (en) 2011-06-16
CN102078620A (zh) 2011-06-01
SV2010003744A (es) 2011-03-15
CU20100230A7 (es) 2012-06-29
ZA201008230B (en) 2011-07-27
US20110130370A1 (en) 2011-06-02

Similar Documents

Publication Publication Date Title
CU20100230A7 (es) Composición farmacéutica que comprende una sal de estroncio, vitamina d y una ciclodextrina
ES2571041T3 (es) Composiciones antimicrobianas
BRPI1010772A2 (pt) composto,e, composição farmacêutica.
PH12012500948A1 (en) Oral compositions containing extracts of garcinia mangostana l. and related methods
GT201200284A (es) Composición farmacéutica
HRP20160807T1 (hr) Visoko koncentrirane farmaceutske formulacije koje sadrže protutijelo anti-cd20
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
BRPI1007018A2 (pt) composto, composição farmacêutica, e , uso de um composto.
BRPI1008906A2 (pt) composto, composição farmacêutica, e, uso de um composto.
CL2011000482S1 (es) Aplicador para cuidado oral.
MX357677B (es) Composiciones inyectables de melfalán que comprenden un derivado de ciclodextrina y métodos de fabricación y uso de las mismas.
WO2012009723A8 (en) C-met modulator pharmaceutical compositions
BR112012000530A8 (pt) uso de uma população de nanopartículas metálicas, e, composição farmacêutica.
AR093645A1 (es) Una formulacion estabilizada de pemetrexed
CO7160079A2 (es) Composiciones líquidas de racecadotrillo
MX343035B (es) Formulacion farmaceutica novedosa que comprende nsaid y ciclodextrina.
EP3067395A4 (en) Ultraviolet radiation-curable composition, and recorded matter
CL2009001973S1 (es) Mostrador.
UA112760C2 (uk) Теобромін у комбінації з гвайфенезином для лікування кашлю
PA8846401A1 (es) Sinergismo antibiótico
CY1118277T1 (el) Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης
EA201071412A1 (ru) Дронедарон для предотвращения кардиоверсии
IT1399492B1 (it) Composizioni farmaceutiche effervescenti contenenti n-acetilcisteina.
BR112013015701A2 (pt) derivado de sulfeto difelina, medicamento e composição farmacêutica contendo o referido derivado
CL2009000054S1 (es) Frasco para cosmeticos.